• Active, not recruiting

NCT02890758: Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803

Updated: Apr 26


NCT02890758: Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803


ALT803

Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803


The purpose of this study is to find the number of natural killer (NK) cells from non-HLA matched donors that can be safely infused into patients with cancer. NK cells are a form of lymphocytes that defend against cancer cells. NK cells in cancer patients do not work well to fight cancer. In this study, the NK cells are being donated by healthy individuals without cancer who are not "matched" by human leukocyte antigen (HLA) genes to patients. After receiving these NK cells, patients may also be given a drug called ALT803. ALT803 is a protein that keeps NK cells alive, helps them grow in number and supports their cancer-fighting characteristics. HLA-unmatched NK cell infusion is investigational (experimental) because the process has not approved by the Food and Drug Administration (FDA).


Sponsor:

David Wald, Case Comprehensive Cancer Center

United States, Ohio


ClinicalTrials.gov Identifier: NCT02890758


Official Title: Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT-803

First Posted : September 7, 2016


Click here to see details on ClinicalTrials.gov

 

Biological: Natural Killer (NK) Cells

Biological: ALT803



ALT-803


ALT-803


Nogapendekin Alfa (Code C107503)

ALT 803

ALT-803

ALT803

Fusion Protein Consisting of IL-15N72D and IL-15RaSu/FC

IL-15N72D/IL-15Ra-Fc


IL-15N72D:IL-15RaSu/Fc Fusion Complex


N 803

N-803

N803

Nogapendekin Alfa

NOGAPENDEKIN ALFA

 

Posts Archive